BPG is committed to discovery and dissemination of knowledge
Articles in Press
5/27/2026 7:05:41 AM | Browse: 3 | Download: 0
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Clinical Trials Study |
| Article Title |
Efficacy of 7-day and 14-day potassium-competitive acid blocker-based bismuth-containing quadruple regimen for Helicobacter pylori infection
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Chang Kyo Oh, Hyun Lim, Jin Hee Noh, Eun Jeong Gong, Seung In Seo, Chang Seok Bang, Yu Jin Kim, Woon Geon Shin, Jin Bae Kim, Hyun Joo Jang and Gwang Ho Baik |
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| HK inno.N, Republic of Korea |
No. KCAB_017 |
|
| Corresponding Author |
Hyun Lim, MD, PhD, Department of Gastroenterology, Hallym University College of Medicine, Hallym University Sacred Heart Hospital, 22 Gwanpyeong-Ro 170-Gil, Dongan-Gu, Anyang 14068, South Korea. hlim77@hallym.or.kr |
| Key Words |
Helicobacter pylori; Potassium-competitive acid blockers; Proton pump inhibitors; Bismuth-containing quadruple therapy; Bismuth-metronidazole; Tetracycline |
| Core Tip |
Bismuth-containing quadruple therapy is recommended as first-line treatment for Helicobacter pylori in regions with high clarithromycin resistance, yet the optimal acid suppressant and treatment duration remain unclear. This multicenter randomized trial is the study to evaluate tegoprazan, a potassium-competitive acid blocker, within a bismuth-metronidazole-tetracycline quadruple regimen. The 14-day tegoprazan-based regimen achieved non-inferior eradication compared with the conventional 14-day proton pump inhibitor-based regimen, whereas the 7-day regimen did not. These results highlight that tegoprazan-based bismuth quadruple therapy requires a 14-day duration to ensure adequate eradication efficacy. |
| Citation |
Oh CK, Lim H, Noh JH, Gong EJ, Seo SI, Bang CS, Kim YJ, Shin WG, Kim JB, Jang HJ, Baik GH. Efficacy of 7-day and 14-day potassium-competitive acid blocker-based bismuth-containing quadruple regimen for Helicobacter pylori infection. World J Gastroenterol 2026; In press |
 |
Received |
|
2026-02-03 01:56 |
 |
Peer-Review Started |
|
2026-02-03 01:57 |
 |
First Decision by Editorial Office Director |
|
2026-03-04 09:09 |
 |
Return for Revision |
|
2026-03-04 09:09 |
 |
Revised |
|
2026-03-17 02:06 |
 |
Publication Fee Transferred |
|
2026-03-25 10:14 |
 |
Second Decision by Editor |
|
2026-05-27 02:42 |
 |
Second Decision by Editor-in-Chief |
|
|
 |
Final Decision by Editorial Office Director |
|
2026-05-27 07:05 |
 |
Articles in Press |
|
2026-05-27 07:05 |
 |
Edit the Manuscript by Language Editor |
|
|
 |
Typeset the Manuscript |
|
|
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc. |
| Copyright |
©Author(s) (or their employer(s)) 2026. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc. |
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.